Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Sep 28, 2019
Filed with the SEC on Nov 1, 2019 and accepted by EDGAR at Nov 1, 2019, 10:56 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-06-30 to 2019-09-28 | $6.27bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-28 | $18.71bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2019-06-30 to 2019-09-28 | $247.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-28 | $741.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-06-30 to 2019-09-28 | $1.54bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-28 | $4.63bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-06-30 to 2019-09-28 | $946.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-28 | $3.36bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-06-30 to 2019-09-28 | $164.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2019-01-01 to 2019-09-28 | $534.0m | us-gaap:InterestExpense |
| Income tax | 3 months2019-06-30 to 2019-09-28 | $62.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-28 | $338.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-06-30 to 2019-09-28 | $760.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2019-01-01 to 2019-09-28 | $2.69bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2019-06-30 to 2019-09-28 | $1.88 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-28 | $6.68 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-06-30 to 2019-09-28 | $1.89 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-28 | $6.73 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-06-30 to 2019-09-28 | 404,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-01-01 to 2019-09-28 | 403,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-01-01 to 2019-09-28 | $3.06bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-28 | $637.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2019-01-01 to 2019-09-28 | $221.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2019-01-01 to 2019-09-28 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-09-28 | $1.27bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-28 | $10.51bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-28 | $56.73bn | us-gaap:Assets |
| Current liabilities | At period end2019-09-28 | $5.84bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2019-09-28 | $16.39bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-09-28 | $661.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2019-09-28 | $29.36bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2019-09-28 | 400,991,227 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-19-000049. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.